Article Text

Download PDFPDF
Tobacco-free blunt wraps: a regulatory conundrum
  1. Grace Kong,
  2. Meghan Elizabeth Morean,
  3. Danielle R Davis,
  4. Krysten W Bold,
  5. Suchitra Krishnan-Sarin
  1. Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA
  1. Correspondence to Dr Grace Kong, Psychiatry, Yale School of Medicine, New Haven, CT 06519, USA; grace.kong{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Cigars (eg, large manufactured cigars, cigarillos) are among the most used combustible tobacco products in the USA.1 2 Some of the popularity of cigars may be driven by the ability to modify them to smoke cannabis ‘blunts’ (ie, hollowed-out cigars filled with cannabis or a mixture of tobacco and cannabis).3–5 Smoking blunts could expose users to greater levels of carcinogens than smoking either cannabis or tobacco alone,6 and, among adolescents and young adults who smoke cigarettes and use cannabis, those who use blunts have greater dependence on nicotine and cannabis than those who use cannabis in forms other than blunts.7 8 Concerningly, blunt use is elevated among individuals who are young, black, or who have substance use disorders.8–10

Blunts can be made using blunt wraps—external wraps typically made of tobacco leaf. However, ‘tobacco-free blunt wraps’ are widely available (eg, convenience stores, tobacco retailers, online). These products do not contain nicotine or tobacco; they are made of products including hemp, banana leaves, palm leaves, and …

View Full Text


  • Twitter @gracekongphd, @DDavisPhD

  • Contributors Study conception and design: GK, MEM. Interpretation of results: GK, MEM, DD, KB, SK-S. Draft manuscript preparation/edits: GK, MEM, DD, KB, SK-S. All authors reviewed the results and approved the final version of the manuscript.

  • Funding This study is funded by Institute of Drug Abuse (NIDA) and the Food and Drug Administration’s Center for Tobacco Products (FDA CTP) grant U54DA036151 (SK-S). Support for authors is also provided by R01DA049878 (GK), K01DA065494 (DD) and R01DA054993 (KWB). The content of this paper is solely the responsibility of the authors and does not represent the official views of the NIH or the FDA.

  • Competing interests None declare.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.